Akèy › Kansè poumon selil ti › Virginia
Etid klinik pou Kansè poumon selil ti nan Virginia
30 etid pou Kansè poumon selil ti ap chèche patisipan nan sit nan Virginia.
Vil nan Virginia
Tèks ofisyèl etid la (Anglè)
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
- Virginia Cancer Specialists - Fairfax /ID# 278298, Fairfax
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07155174The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- University of Virginia, Charlottesville
- NEXT Virginia, Fairfax
Ap rekriteFaz 1
Laj 19 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06586957Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
- Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Blacksburg
- Virginia Oncology Associates, Chesapeake
- Virginia Oncology Associates, Hampton
- ak 8 plis
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07226999A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- Blue Ridge Cancer Care - Blacksburg /ID# 281583, Blacksburg
- Virginia Cancer Specialists - Fairfax /ID# 280710, Fairfax
- Shenandoah Oncology /ID# 280699, Winchester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07365241A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Inova Schar Cancer Institute Clinical Trials, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07488676Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05983432A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
- NEXT Virginia, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07730021A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
- Site 1002, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07407933BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07625644A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07218146A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Oncology & Hematology Associates of Southwest Virginia, Inc., Roanoke
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06646276AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Fairfax
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Sep 4, 2026 · NCT07038343Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Virginia Cancer Specialists, Fairfax
- Hematology Oncology Associates of Fredericksburg, Inc., Fredericksburg
- Virginia Commonwealth University School of Medicine, Richmond
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 1, 2026 · NCT06712355Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
- Universtiy of Virginia, Charlottesville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07057791A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT06892548Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
- Next Virginia, Fairfax
Ap rekriteFaz 1
Laj 18 a 99 · Tout sèks · Mizajou Aug 21, 2026 · NCT07531095A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
- Oncology & Hematology Associates of Southwest Virginia, Blacksburg
- Virginia Cancer Specialists Research Institute, Fairfax
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT06095505A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07749586DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Virginia Commonwealth University Health- Adult Outpatient Pavilion, Richmond
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 23, 2026 · NCT05882058A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- NEXT Virginia, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 15, 2026 · NCT05652686A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
- NEXT Oncology Virginia, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 9, 2026 · NCT07174583Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
- University of Virginia Comprehensive Cancer Center, Charlottesville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 26, 2026 · NCT07149363A Study of LY4175408 in Participants With Advanced Cancer
- NEXT Virginia, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 23, 2026 · NCT07046923AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
- NEXT Oncology Virginia, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 2, 2026 · NCT07454642MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
- University of Virginia Health System, Charlottesville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 29, 2026 · NCT05903092Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
- NEXT Oncology Virginia, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 7, 2026 · NCT07424547Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
- VCU Community Memorial Health Center, South Hill
- ak 1 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Mar 30, 2026 · NCT06769126Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- NEXT Virginia, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Feb 18, 2026 · NCT07030257A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 102, Fairfax
- Research Site 112, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Nov 21, 2025 · NCT05914116Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.